Drug Database
Back to search

Sweden· SE-20190102000108

Deflazacort XGX Pharma 30 mg Tablett

A deflazacort product containing deflazacort, registered in Sweden by XGX Pharma ApS. The same ATC class is registered in 8 of our 19 countries.

ATC H02AB13

Checked against Swedish Medical Products Agency (Sweden) on

Informational only — not a medical device.

SOURCE REGISTER · SESwedish Medical Products Agency (Sweden)normalisedDeflazacort XGX Pharma 30 mg TablettATCH02AB13REGISTER NO.SE-20190102000108PACKS LISTED1CHECKEDOctober 1, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about deflazacortAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Deflazacort is registered in 8 of 19 countries.

Countries holding a registration under ATC H02AB13 (deflazacort), each read from that country’s own register.

  • This record: Sweden, from Swedish Medical Products Agency (Sweden)
  • 3 of them publish a price we can compare per daily dose
Search deflazacort products by name

Deflazacort · ATC H02AB13

8 / 19 countries

  • Denmark
  • Finlandprice
  • Germany
  • Netherlands
  • Norwayprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of deflazacort costs, country by country.

Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Deflazacort · price per daily dose (15 mg)

USD · FX 28 Sept 2026

  • ES Spain$0.19
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swedish Medical Products Agency (Sweden)
Active substance
Deflazacort
Manufacturer
XGX Pharma ApS
Country
Sweden (SE)
ATC code
H02AB13
ATC class
Deflazacort
Defined daily dose
15 mg, O
Reimbursed
Not published by this register
Source register
Swedish Medical Products Agency (Sweden)
Last checked
October 1, 2026

Packs & prices · 1

  • se_varunummer
    20190102000108

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for deflazacort.

Graded by severity as the source publishes them — 129 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check deflazacort against other medicinesHow interaction checks work

Deflazacort · interactions on record

434 records

  • 129 severe
  • 297 moderate
  • 8 minor

Most severe, free to view

  • AprepitantA04AD12severe
  • LonafarnibA16AX20severe
  • DesirudinB01AE01severe
  • BerotralstatB06AC06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Deflazacort in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deflazacort products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

  • Germany · Calcort, Deflazacort Galen
  • Denmark · Deflazacort Vital Pharma Nordic
  • Spain · Defal, Deflazacort Cinfa
  • Finland · Deflazacort Vital Pharma Nordic
  • United Kingdom (Northern Ireland) · Calcort
  • Italy · Decor, Deflan
  • Netherlands · Deflazacort Xgx Pharma
  • Norway · Deflazacort Xgx Pharma
  • Portugal · Deflazacorte Acizan, Deflazacorte Almus

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/49d37b00-85a7-497e-a61e-406cd2e946db
GET /v1/drugs/49d37b00-85a7-497e-a61e-406cd2e946db?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "lakemedelsverket",
  "doc_types": [
    "SmPC",
    "PL"
  ],
  "se_npl_id": "20190102000108",
  "product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20190102000108",
  "product_doc_link": "https://docetp.mpa.se/LMF/Deflazacort%20XGX%20Pharma%20tablet%20SmPC_09001bee84824c8a.pdf"
}
API referenceMCP serverPlans

See everything about deflazacort.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console